Publication Name	World Journal of Clinical Oncology
Manuscript ID	33286
Country	United States

Received	2017-02-10 09:50
Peer-Review Started	2017-02-14 10:38
To Make the First Decision	2017-03-06 18:16
Return for Revision	2017-03-07 15:41
Revised	2017-03-18 01:04
Second Decision	2017-04-10 18:35
Accepted by Journal Editor-in-Chief	2017-04-10 18:59
Accepted by Company Editor-in-Chief	2017-04-19 16:53
Articles in Press	2017-04-19 16:53
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2017-05-26 04:53
Publish the Manuscript Online	2017-06-02 05:29

ISSN	2218-4333 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Minireviews
Article Title	Immunotherapy in pancreatic cancer: Unleash its potential through novel combinations
Manuscript Source	Invited Manuscript
All Author List	Songchuan Guo, Merly Contratto, George Miller, Lawrence Leichman and Jennifer Wu
Funding Agency and Grant Number
Corresponding Author	Jennifer Wu, MD, Associate Professor, Division of Hematology and Oncology, Perlmutter Cancer Center, New York University School of Medicine, 462 First Ave, BCD556, New York, NY 10016, United States. jennifer.wu@nyumc.org
Key Words	Immunotherapy; Pancreatic cancer; Anti-programmed cell death protein-1; Anti-programmed cell death protein-ligand1; Anti-cytotoxic T lymphocyte antigen-4; Single therapy; Combination therapies; Radiation therapy; GVAX; CRS-207; CD40 agonist
Core Tip	Pancreatic cancer is the third leading cause of cancer mortality in both men and women in the United States. Pancreatic cancer is one of nonimmunogenic cancers that lacks of optimal treatments especially from immunotherapy prospective. Therefore, combining immune checkpoint therapies with other treatment modalities in pancreatic cancer will be the best strategy to achieve better and more durable clinical responses by enhancing cytotoxic T-cell responses.
Publish Date	2017-06-02 05:29
Citation	Guo S, Contratto M, Miller G, Leichman L, Wu J. Immunotherapy in pancreatic cancer: Unleash its potential through novel combinations. World J Clin Oncol 2017; 8(3): 230-240
URL	http://www.wjgnet.com/2218-4333/full/v8/i3/230.htm
DOI	http://dx.doi.org/10.5306/wjco.v8.i3.230

Full Article (PDF)	WJCO-8-230.pdf
Full Article (Word)	WJCO-8-230.doc
Manuscript File	33286-Review.docx
Answering Reviewers	33286-Answering reviewers.pdf
Audio Core Tip	33286-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	33286-Conflict-of-interest statement.pdf
Copyright License Agreement	33286-Copyright assignment.pdf
Peer-review Report	33286-Peer-review(s).pdf
Journal Editor-in-Chief Review Report	33286-Journal editor-in-chief review report.pdf
Scientific Misconduct Check	33286-Scientific misconduct check.pdf
Scientific Editor Work List	33286-Scientific editor work list.pdf